Corten and Ampersand acquire Beacon Intelligence
The drug development intelligence platform serves over 300 customers including 24 of the 30 largest pharmaceutical companies and was carved out from Hanson Wade Group.
Takeaways
- Beacon Intelligence is a drug development intelligence platform for life sciences R&D.
- Corten Capital and Ampersand Capital Partners is acquiring Beacon Intelligence.
- The business serves life sciences and pharmaceutical R&D.
Corten Capital and Ampersand Capital Partners have acquired Beacon Intelligence, a drug development intelligence platform serving over 300 customers globally.
The company was carved out from life sciences events operator Hanson Wade Group, which was backed by Graphite Capital.
The platform’s user base includes 24 of the world’s 30 largest pharmaceutical companies, and it employs 135 people.
Debt financing was provided by HSBC UK Leveraged Finance and HSBC Asset Management, alongside equity from Corten Capital II and Ampersand Capital Partners.
The transaction is the third investment from Corten Capital II, a €680 million fund that closed in March 2024.
Corten Capital is the majority owner, backing CEO Rob Poolman and chair Sati S.; Ampersand participated as a minority co-investor, with General Partner David Anderson joining the board.
Get tomorrow morning's tape in your inbox.
Yesterday's platforms, add-ons, recaps, and exits, cleaned up before the workday starts.